K-numberK253861
Device nameACORYS MAPPING SYSTEM
ApplicantCorify Care S.L
Product codeDQK
Device classClass II
Decision dateApr 13, 2026
DecisionSubstantially Equivalent
Regulation870.1425
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The ACORYS MAPPING SYSTEM is a non-invasive cardiac mapping device that acquires electrocardiographic signals from 128 body surface sensors and combines them with a 3D torso model to generate three-dimensional electroanatomic maps of the heart. It is intended for acquisition, analysis, display, and storage of cardiac electrophysiological data for patients with cardiac arrhythmias and/or electrical disorders in adults, for use in medical consultations or hospitals during electrophysiological interventions on intact skin only.

Technological characteristics

The ACORYS system uses 128 sensors (versus the predicate's 256) and generates cardiac geometry automatically via 3D torso reconstruction from integrated sensors, or accepts pre-existing CT scans. The predicate device requires external CT segmentation and manual sensor localization. Both systems solve the cardiac inverse problem to transform body surface signals into epicardial maps; mathematical modeling showed ACORYS achieved equivalent or improved localization accuracy compared to the predicate.

Test standards cited

EN 60601-1:2005+A2:2020, IEC 60601-2-27:2014, IEC 60601-1-6:2010+A2:2021, EN60601-1-2:2014+A1:2020, IEC 62304:2006+A1:2015, ISO 14971:2019/A11:2021, ISO 10993-1:2020, ISO 10993-5:2009, ISO 10993-10:2021, ISO 10993-18:2020, and ISO 10993-23:2021. Testing included electrical safety, electromagnetic compatibility, software verification, biocompatibility, and 3D scan accuracy validation.

Substantial equivalence argument

The ACORYS MAPPING SYSTEM is substantially equivalent to the Medtronic CardioInsight predicate device because both are programmable diagnostic computers for non-invasive cardiac electrical mapping with identical indications for use, intended patient populations, and clinical purpose. Clinical evaluation in 199 patients demonstrated performance comparable to the predicate with no device-related adverse events, and bench testing showed mathematical equivalence or superiority in localization accuracy despite technological differences.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →